Fig. 4: MCED test CSO prediction accuracy observed in real-world data is consistent with previous independent clinical studies.
From: Real-world data and clinical experience from over 100,000 multi-cancer early detection tests
A Overall CSO accuracy observed in real-world patients with a cancer diagnosis and reported cancer type (n = 237) (purple), CCGA validation study (green)23, and PATHFINDER clinical study (gold)24. B CSO prediction accuracy by CSO in the real-world dataset (purple) and CCGA (green) datasets (PATHFINDER CSO data was not included due to low sample size per CSO). CSO prediction accuracy is the fraction of MCED test–predicted CSOs that match the diagnosed cancer. Aggregate CSO prediction accuracy for all CSOs with less than 10 observations in the real-world population is displayed as “N < 10 CSOs”. Patient population for (B) is the number of patients with an assigned clinical CSO (n = 232). The CSO accuracy percent and number of correct CSO predictions out of all CSO predictions given for patients with a reported cancer type per A dataset or B CSO category are noted above each graph. Error bars denote the 95% binomial confidence interval. Source data are provided as a Source Data file. CCGA3 Circulating Cell-free Genome Atlas substudy 3, CSO cancer signal origin.
